StreetInsider.com News Articles

Stoke, Biogen to present 4-year zorevunersen data at epilepsy congress

Tue, 01 Sep 2026 07:30:47 -0400

Stoke Therapeutics (NASDAQ: STOK) and Biogen (NASDAQ: BIIB) announced plans to present clinical data on zorevunersen, an investigational treatment for Dravet syndrome, at the 16th European Epilepsy Congress (EEC) in Athens, Greece, running September 5–9.

The presentations include the first medical meeting disclosure of 4-year results from ongoing Phase 1/2a open-label extension (OLE) studies. According to the companies, improvements in cognition and behavior were sustained through four years, alongside seizure reductions and a generally well-tolerated safety profile. New sub-analyses also examined effects on the most severe seizure types and patient quality of life.

Of the 81 patients enrolled in the Phase 1/2a

Stoke, Biogen to present 4-year zorevunersen data at epilepsy congress

Tue, 01 Sep 2026 07:30:47 -0400

Of the 81 patients enrolled in the Phase 1/2a

Stoke, Biogen to present 4-year zorevunersen data at epilepsy congress

Tue, 01 Sep 2026 07:30:47 -0400

Of the 81 patients enrolled in the Phase 1/2a

Stoke, Biogen to present 4-year zorevunersen data at epilepsy congress

Tue, 01 Sep 2026 07:30:47 -0400

Of the 81 patients enrolled in the Phase 1/2a

Stoke, Biogen to present 4-year zorevunersen data at epilepsy congress

Tue, 01 Sep 2026 07:30:47 -0400

Of the 81 patients enrolled in the Phase 1/2a

Stoke, Biogen to present 4-year zorevunersen data at epilepsy congress

Tue, 01 Sep 2026 07:30:47 -0400

Of the 81 patients enrolled in the Phase 1/2a

Stoke Therapeutics and Biogen Announce Presentations of Clinical Data from Studies of Zorevunersen, an Investigational Medicine for the Treatment of Dravet Syndrome, at the 16th European Epilepsy Cong

Tue, 01 Sep 2026 07:30:00 -0400

–4-year data from the Phase 1/2a open-label extension (OLE) studies support the potential disease-modifying effects of zorevunersen–

–Improvements in cognition and behavior sustained through 4 years, in addition to durable seizure reductions and a generally well-tolerated safety profile–

–New data from sub-analyses of patients treated with zorevunersen in the Phase 1/2a OLEs include effects on severe seizures and quality of life–

BEDFORD, Mass. and CAMBRIDGE, Mass., Sept. 01, 2026 (GLOBE NEWSWIRE) -- Stoke Therapeutics, Inc. (Nasdaq: STOK), a biotechnology company dedicated to restoring protein expression by harnessing the body’s potential with

Stoke Therapeutics and Biogen Announce Presentations of Clinical Data from Studies of Zorevunersen, an Investigational Medicine for the Treatment of Dravet Syndrome, at the 16th European Epilepsy Cong

Tue, 01 Sep 2026 07:30:00 -0400

–4-year data from the Phase 1/2a open-label extension (OLE) studies support the potential disease-modifying effects of zorevunersen–

–Improvements in cognition and behavior sustained through 4 years, in addition to durable seizure reductions and a generally well-tolerated safety profile–

–New data from sub-analyses of patients treated with zorevunersen in the Phase 1/2a OLEs include effects on severe seizures and quality of life–

Stoke Therapeutics and Biogen Announce Presentations of Clinical Data from Studies of Zorevunersen, an Investigational Medicine for the Treatment of Dravet Syndrome, at the 16th European Epilepsy Cong

Tue, 01 Sep 2026 07:30:00 -0400

–4-year data from the Phase 1/2a open-label extension (OLE) studies support the potential disease-modifying effects of zorevunersen–

–Improvements in cognition and behavior sustained through 4 years, in addition to durable seizure reductions and a generally well-tolerated safety profile–

–New data from sub-analyses of patients treated with zorevunersen in the Phase 1/2a OLEs include effects on severe seizures and quality of life–

Stoke Therapeutics and Biogen Announce Presentations of Clinical Data from Studies of Zorevunersen, an Investigational Medicine for the Treatment of Dravet Syndrome, at the 16th European Epilepsy Cong

Tue, 01 Sep 2026 07:30:00 -0400

–4-year data from the Phase 1/2a open-label extension (OLE) studies support the potential disease-modifying effects of zorevunersen–

–Improvements in cognition and behavior sustained through 4 years, in addition to durable seizure reductions and a generally well-tolerated safety profile–

–New data from sub-analyses of patients treated with zorevunersen in the Phase 1/2a OLEs include effects on severe seizures and quality of life–

JPMorgan Reinstates Stoke Therapeutics (STOK) at Overweight

Fri, 21 Aug 2026 03:28:08 -0400

JPMorgan analyst Jessica Fye reinstates coverage on Stoke Therapeutics (NASDAQ: STOK) with a Overweight rating and a price target of $40.00.

For an analyst ratings summary and ratings history on Stoke Therapeutics click here. For more ratings news on Stoke Therapeutics click here.

Shares of Stoke Therapeutics closed at $31.40 yesterday.

Form 4 Stoke Therapeutics, Inc. For: Aug 14 Filed by: Ticho Barry

Tue, 18 Aug 2026 20:30:00 -0400

si-local-file:///var/storage/secattach/20260818/26946011.html

Form 4 Stoke Therapeutics, Inc. For: Aug 14 Filed by: Ticho Barry

Tue, 18 Aug 2026 20:30:00 -0400

si-local-file:///var/storage/secattach/20260818/26946011.html

Form 4 Stoke Therapeutics, Inc. For: Aug 14 Filed by: Kaye Edward M. MD

Tue, 18 Aug 2026 20:29:00 -0400

si-local-file:///var/storage/secattach/20260818/26946010.html

Form 4 Stoke Therapeutics, Inc. For: Aug 14 Filed by: Kaye Edward M. MD

Tue, 18 Aug 2026 20:29:00 -0400

si-local-file:///var/storage/secattach/20260818/26946010.html

Form 4 Stoke Therapeutics, Inc. For: Aug 14 Filed by: Allan Jonathan

Tue, 18 Aug 2026 20:27:00 -0400

si-local-file:///var/storage/secattach/20260818/26946006.html

Form 4 Stoke Therapeutics, Inc. For: Aug 14 Filed by: Allan Jonathan

Tue, 18 Aug 2026 20:27:00 -0400

si-local-file:///var/storage/secattach/20260818/26946006.html

Stoke Therapeutics Announces Inducement Grants Under Nasdaq Listing Rule 5635(C)(4)

Tue, 18 Aug 2026 16:01:00 -0400

BEDFORD, Mass.--(BUSINESS WIRE)-- Stoke Therapeutics, Inc. (Nasdaq: STOK) is a biotechnology company dedicated to restoring protein expression by harnessing the body’s potential with RNA medicine and has a lead investigational medicine, zorevunersen, in development as a first-in-class potential disease-modifying treatment for Dravet syndrome. The Company today announced that, effective on August 17, 2026, it granted stock options to purchase an aggregate of 70,950 shares of common stock to seven new employees, as a material inducement to their employment in accordance with Nasdaq Listing Rule 5635(c)(4).

The stock options that were granted have an exercise

Stoke Therapeutics Announces Inducement Grants Under Nasdaq Listing Rule 5635(C)(4)

Tue, 18 Aug 2026 16:01:00 -0400

The stock options that were granted have an exercise

Stoke Therapeutics Announces Inducement Grants Under Nasdaq Listing Rule 5635(C)(4)

Tue, 18 Aug 2026 16:01:00 -0400

The stock options that were granted have an exercise

Stoke Therapeutics Announces Inducement Grants Under Nasdaq Listing Rule 5635(C)(4)

Tue, 18 Aug 2026 16:01:00 -0400

The stock options that were granted have an exercise

Form SCHEDULE 13G/A Stoke Therapeutics, Inc. Filed by: Lynx1 Capital Management LP

Fri, 14 Aug 2026 16:40:00 -0400

si-local-file:///var/storage/secattach/20260814/26931825.html

Form SCHEDULE 13G/A Stoke Therapeutics, Inc. Filed by: Lynx1 Capital Management LP

Fri, 14 Aug 2026 16:40:00 -0400

si-local-file:///var/storage/secattach/20260814/26931825.html

Form SCHEDULE 13G/A Stoke Therapeutics, Inc. Filed by: TORONTO DOMINION BANK

Wed, 12 Aug 2026 16:10:00 -0400

si-local-file:///var/storage/secattach/20260812/26912919.html

Form SCHEDULE 13G/A Stoke Therapeutics, Inc. Filed by: TORONTO DOMINION BANK

Wed, 12 Aug 2026 16:10:00 -0400

si-local-file:///var/storage/secattach/20260812/26912919.html